Petros Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Petros Pharmaceuticals, Inc. (PTPI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.48% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2023-03-31
- Petros Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 0.48%, a 97.85% decline from fiscal 2021.
- Petros Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 22.31%.
- Petros Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was -2.68%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2022-12-31 | 0.48% 10-K · filed 2023-03-31 |
| 2021-12-31 | 22.31% 10-K · filed 2023-03-31 |
| 2020-12-31 | -2.68% 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |